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c-REL is a Transcriptional Target of Mesoderm Inducer in Xenopus Like 1 
(MIXL1) 
 
 
Aaron Raymond, M.S. 
 
Supervisory Professor: Lalitha Nagarajan, Ph.D. 
 
 
MIXL1, an evolutionarily conserved, paired-type homeobox transcription 
factor induced by BMP4/TGFb signaling, is a critical regulator of embryonic and 
adult hematopoiesis.  Several lines of evidence implicate MIXL1 in hematopoietic 
transformation: (i) Aberrant MIXL1 expression is seen in human CML ( Chronic 
Myelogenous Leukemia) in blast crisis, AML (Acute myelogenous leukemia), B 
cell lymphomas and pediatric ALL (Acute lymphocytic leukemia). (ii) Retroviral 
transduction of Mixl1 induces AML in murine models.  Nonetheless, mechanisms 
underlying MIXL1 mediated proliferative, survival advantages are unknown. 
The goal of my studies is to understand if and how aberrant MIXL1 
expression contributes to leukemogenesis.  As a first step, I sought to determine 
transcriptional targets of MIXL1.  Using MIXL1 overexpression lines established 
in the human myelomonocytic leukemia cell line, U937, I performed global 
chromatin immunoprecipitation coupled sequencing (ChIP-Seq), expression 
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profiling studies I identified several putative targets. Of these, the proto-oncogene 
c-REL was an important target. Both ectopically expressed and endogenous 
MIXL1 bound REL promoters in myelogenous leukemia cells.  Furthermore, 
cREL was induced under MIXL1 over-expression conditions in the leukemic cell 
line U937.  Targeted shRNA mediated knockdown of endogenous MIXL1 in AML 
cell lines down regulated REL expression. 
c-REL the cellular homolog of the viral oncogene v-rel encoded by the 
oncogenic reticuloendotheliosis retrovirus, is a member of the Nf-κB/Rel gene 
family. c-REL transcriptionally activates proliferation and immune response and 
represses apoptosis through upregulation of anti-apoptotic genes.  c-REL plays a 
critical role in hematopoietic differentiation.  It is required for B-cell differentiation, 
and dendritic cells to activate T cells.  In the myeloid lineage, c-REL is critical for 
macrophage mediated innate immunity.  My findings suggest that transcriptional 
up regulation of REL by MIXL1, therefore would promote survival or proliferation 
through activation of the Nf-κB pathway in AML cells.  Consistent with these 
established activities of c-REL, expression of two anti-apoptotic genes BCL2A1 
and BCL2L1 increased under MIXL1 over-expression conditions and decreased 
under conditions of MIXL1 knockdown by targeted shRNA in U937 cells.  In 
summary, my studies identify c-REL to be a novel mediator of MIXL1-induced 
survival signals in leukemia. 
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ABBREVIATIONS – Genes and Proteins of Interest 
ABL1 – c-ABL, Abelson murine leukemia viral oncogene homolog 1. A proto-
oncogene tyrosine kinase associated with CML. 
Activin A – A cytokine belonging to the TGF-β superfamily. 
ALK2 (ACVR1) – Activin A receptor, type 1, a BMP-type member of the TGF-β 
receptor superfamily.  Can be activated by Activin and BMP. 
ALK3 (BMPR1A) – Bone Morphogenic Protein receptor, type 1A, a BMP-type 
member of the TGF-β receptor superfamily.  Can be activated by BMP proteins. 
ALK6 (BMPR1B) – Bone Morphogenic Protein receptor, type 1B, a BMP-type 
member of the TGF-β receptor superfamily.  Can be activated by  BMP proteins. 
AVCR2A – Activin type 2 receptor A, a BMP-type member of the TGF-β receptor 
superfamily. Can be activated by Activin and BMP. 
ALX4 – ALX Homeobox 4, a paired-type homeobox transcription factor.  
APBB2 – Amyloid beta A4 precursor protein-binding family B member 2. 
BCL2 – B-cell lymphoma 2, an anti-apoptotic gene that regulates chytochrome-c 
mediated apoptosis. 
BCL2A1 – BCL2-related protein A1, a BCL2 family member and an anti-
apoptotic gene that regulates chytochrome-c mediated apoptosis. 
BCL2L1 – BCL2-like protein 1, a BCL2 family member and an anti-apoptotic 
gene that regulates chytochrome-c mediated apoptosis. 
BMP4 – Bone Morphogenic Protein 4, a cytokine belonging to the TGF-β 
superfamily. 
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BMPR1 – Bone Morphogenic Protein receptor, type 2, a BMP-type member of 
the TGF-β receptor superfamily.  Can be activated by  BMP proteins. 
BRCA1–  Breast Cancer 1, early onset, a RING zinc finger protein. 
CAMKK2 –  Calcium/calmodulin-dependent protein kinase kinase 2, a 
calmodulin-dependant serine/threonine kinase. 
CDX2 – Caudal type homeobox 2, a caudal-related homeobox transcription 
factor.  
DLX1 –Distal-less homeobox 1, a homeobox transcription factor with similarity to 
the Drosphilia distal-less gene. 
DLX4 –Distal-less homeobox 4, a homeobox transcription factor with similarity to 
the Drosphilia distal-less gene. 
EGR1 – Early growth response 1, a C2H2-type zinc-finger transcription factor. 
EIF1 – Eukaryotic translation initiation factor 1. 
EOMES – Eukaryotic translation initiation factor 1. 
GSC – Goosecoid homeobox, a paired-type homeobox transcription factor. 
HHEX– Hematopoietically-expressed homeobox, a homeobox transcription 
factor. 
HLX – H2.0-like homeobox, a homeobox transcription factor. 
HOXA9 –Homeobox A9, a homeobox transcription factor of the cluster A 
subgroup. 
IL18R1 –Interleukin 18 receptor 1, an Interleukin cytokine receptor, that 
specifically binds to interleukin 18.   
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MIXL1 –Mesoderm inducer in Xenopus like 1, a paired type homeobox 
transcription factor. 
MZF1 – Myeloid zinc finger 1, a C2H2-type zinc finger transcription factor. 
NEUROD1 – Neuronal differentiation 1, a helix-loop-helix transcription factor. 
NF-κB – A ubiquitous transcription factor protein dimer that consists of either NF-
κB1/p50 or NF-κB2/p49 in complex with REL, RELA, or RELB.  The most 
prevalent form is NF-κB1/p50 in complex with RELA. 
NFKB1 –Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, a 
NF-κB/REL-family transcription factor that produces the protein NF-κB1/p50, part 
of the most prevalent “canonical” NF-κB protein dimer alongside RELA. 
NFKB2 – Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, a 
NF-κB/REL-family transcription factor that produces the protein NF-κB2/p49. 
NFKBIA,B,E – Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha, beta, and epsilon, a family of proteins that bind to NF-κB/REL 
dimers to inhibit their function. 
NKX2-1 – NK2 homeobox 1, a homeobox transcription factor. 
OTX2 – orthodenticle homeobox 2, a paired-type homeobox transcription factor. 
PCGF2 – Polycomb group RING finger protein 2, a RING finger containing 
protein. 
PML–Promyelocytic leukemia protein, is a homeobox transcription factor. 
POU4F2 –POU class 4 homeobox 2, is a homeobox transcription factor. 
 xiv 
 
c-REL – v-rel avian reticuloendotheliosis viral oncogene, a NF-κB/REL-family 
transcription factor and family member that shares the most sequence homolog 
to the viral oncogene. 
RELA – v-rel avian reticuloendotheliosis viral oncogene homolog A (p65), a NF-
κB/REL-family transcription factor and part of the most prevalent “canonical” NF-
κB protein dimer alongside NF-κB1/p50.  
RELB – v-rel avian reticuloendotheliosis viral oncogene homolog B, a NF-
κB/REL-family transcription factor. 
RUNX1 – RUNT related transcription factor 1, a transcription factor that regulates 
hematopoietic stem cell differentiation. 
SLC39A13 – Solute carrier family 39 (zinc transporter), member 13, a 
transmembrane zinc transporter. 
SMAD – A family of signal transduction proteins that transcriptionally regulate 
targeted genes in response to TGF-β family signaling pathways. 
SMYD5 – SMYD family member 5, a methyltransferase. 
Sp1 – Sp1 transcription factor, a SP/KLF family zinc finger transcription factor. 
T –  A gene that encodes the T box transcription factor Brachyury. 
TBX6 – T-box 6, a T box transcription factor. 
TBX20 – T-box 20, a T box transcription factor. 
TGF-β – Transforming growth factor beta, a family of cytokines that regulate 
proliferation, differentiation, migration, and other pathways through interaction 
with TGF-β receptors.  Part of the same superfamily of cytokines as BMP and 
Activin. 
 xv 
 
VEG-FR – Vascular endothelial growth factor Receptor, a family of receptors that 
interact with VEGF, and are important for vasculogenesis and angiogenesis. 
YES1 – v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1, src family 
tyrosine kinase and homolog to the Yamaguchi sarcoma virus oncogene. 
ZP3 – Zona pellucida glycoprotein 3 (sperm receptor),  an extracelular matrix 
protein. 
 xvi 
 
 
ABBREVIATIONS – Other 
6-FAM – 6-Carboxyfluorescein, a common fluorescent dye used for attachment 
to oligonucleotides, especially in real time PCR techniques. 
ALL – Acute lymphoblastic leukemia. 
AML – Acute myelogenous leukemia. 
ChIP – Chromatin Immunoprecipitation, A technique for identification of in vitro or 
in vivo interactions between proteins and chromosomal DNA by DNA/protein 
crosslinking, immunoprecipitation and then DNA extraction. 
ChIP-qPCR – ChIP-coupled qPCR, a technique for quantifying and evaluating 
the prevalence of a DNA/protein interaction by using quantitative PCR against 
desired targets on DNA samples produced by ChIP. 
ChIP-Seq  – ChIP-coupled sequencing, a high throughput technique for 
identifying, quantifying, and evaluating the prevalence of DNA/protein 
interactions by using high-throughput sequencings techinues on DNA samples 
produced by ChIP. 
CML – Chronic myelogenous leukemia. 
Ct (qPCR) – Cycle Threshold, a raw data value representing the prevalence of 
nucleic acid sequencing in a quantitative PCR reaction.  The Ct value is the cycle 
of PCR reaction where the fluorescence signal passed a set threshold, so lower 
Ct values mean higher abundance of DNA sequence. 
DMSO – Dimethyl sulfoxide. 
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Dorsomorphin –Dorsomorphin dihydrochloride, a serine/threonine kinase 
inhibitor which can potently inhibit  for BMP/Acitivin related receptor kinases and 
AMP-activated protein kinase (AMPK).   
Doxorubicin – A cancer chemotherapy commonly used for leukemia and other 
cancers.  It functions by intercalating DNA, blocking DNA replication. 
ECL Reagent – Enhanced chemiluminescence reagent, a luminol-based 
detection reagent used for western blotting. 
FLAG – A polypeptide epitope tag.  Amino Acid Sequence: DYKDDDDK 
Fibrodysplasia ossificans progressiva – A rare chronic disease that causes 
fibrous tissues to ossify, form bone tissue, when injured or spontaneously.  
Mutations in ACVR1 have been implicated in this disease. 
Gag-pol – Group Antigens (ag)-Pol, A retroviral polyprotein that is cleaved to 
create the non-viral envelope proteins required for producing a retrovirus, 
including the reverse transcriptase (Pol) and retroviral core proteins (Gag).  An 
expression construct containing this is used alongside an envelope-producing 
construct and the desired retroiviral expression vector to create a replication-
dead retrovirus. 
HA –Human influenza hemagglutinin, commonly used as an epitope tag. The 
tag’s Amino Acid Sequence: YPYDVPDYA 
Iowa Black FQ – An IDT (Integrated DNA Technologies)-developed quencher 
with an absorbance range of 420 to 620 nm.  The main use in this case is to 
attachment to oligonucleotides, to quench the activity of the nearby 6-FAM group. 
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LDN-193189 – A serine/threonine kinase inhibitor derived from dorsomorphin to 
be a more specific inhibitor to BMP/Activin related ALKs.  
MTS – 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, a tetrazole that, when present with phenazine 
methosulfate (PMS), produces a formazan product with the absorbance range of 
490-500 nm, when reduced by cellular enzymes.   
qPCR – Quantitative or Real-Time Polymerase Chain Reaction, a quantitative 
form of polymerase chain reaction where an fluorescence activity is tested for at 
the end of each cycle of PCR, with the activation of a fluorescent dye being 
directly linked with each successful polymerase reaction. 
SELEX– systematic evolution of ligands by exponential enrichment.  An 
approach for identifying the binding site of proteins on RNA or DNA in vitro. 
shRNA – small hairpin RNA, a short sequence of RNA, usually artificially 
produced, to silence the targeted gene through RNA interference/post 
transcriptional gene silencing.  
TCGA – The Cancer Genome Atlas, http://cancergenome.nih.gov/ 
TSE – Transcriptional Sequence End, the predicted endpoint for transcription of 
a gene locus.  In this dissertation, TSE refers to a 5 kb untranscribed region 
downstream the endpoint for the purpose of defining the location of ChIP peaks 
in reference to nearby gene loci. 
TSS – Transcriptional Start Site, the transcriptional start site of a gene locus.  In 
this dissertation, the promoter region is defined as a 5 kb region upstream of the 
transcriptional start site. 
Chapter 1. Introduction 
1. MIXL1 
 MIXL1, Mesoderm Inducer in Xenopus Like 1, is the human ortholog of 
Xenopus Mix.1, required for mesoderm development.  MIXL1 is the sole human 
member of the Mix/Bix homeobox sub-family.  While the Mix/Bix family is 
comprised of multiple genes in Xenopus laevis (Mix.1-4, Bix.1-4, and Mixer) and 
Danio Rerio (Bon, Mxtx1 and Mxtx2); birds and mammals each contain only one 
ortholog for Mix.1 and no pseudogenes (1-3).  The Mix/Bix family has been well 
characterized as major regulators of mesoderm and endoderm specification in 
early embryonic development in Xenopus.  Expression of Mixl1, the mouse 
ortholog of MIXL1 was detected at day 5.5 post coitum (dpc) in the visceral 
endoderm (3, 4), primitive streak and in the nascent mesoderm between days 
6.5-8.0 dpc (3-5).  Mixl1-/- embryos died before days 10.5 dpc with multiple 
defects (6).  Enforced expression of Mixl1 in mouse ES cells promoted 
mesodermal, hemangioblastic and hematopoietic progenitors (7).   
As a paired-type subfamily, Mix/Bix family proteins are characterized by 
60 amino acid segments homologous to that of the paired type homeobox 
transcription factors.  Paired-type homeodomain-containing proteins 
preferentially bind to DNA at a sequence motif of “TAAT”.  Mix/Bix family are 
classified as Q50 paired-types, denoting both a glutamine in the 50th amino acid 
in the homeodomain, and a preference for a 3 nucleotide spacer of sequence 
“TGA” between both halves of the dimer motif i.e TAATTGAATTA (8, 9).  The 
preference to a TAATNNNATTA sequence was confirmed for mouse Mixl1(10).  
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While the Mix/Bix family is well characterized to bind as a dimer with other 
mesoderm-specific homeodomain-containing proteins, including other Mix/Bix 
family members, Gsc and Siamois (11), human MIXL1 was found to interact, in 
mammalian a high throughput two-hybrid screen, with homeodomain-containing 
proteins associated with a diverse set of lineages, including the neuronal-
associated POU4F2, OTX2, and DLX1, thyroid-associated NKX2-1, and dermis-
associated ALX4 (12).  In the same study, MIXL1 interacted with the basic helix-
loop-helix transcription factor NEUROD1, implying that MIXL1 may have the 
potential to interact with non-homeobox proteins.   
 
2. MIXL1 is regulated by TGF-β/BMP Pathways 
 One of the developmental roles of the BMP ligand BMP4 is the induction 
of mesoderm during early embryogenesis, and in Xenopus, Mix.1 is an 
necessary intermediate for BMP4 induction of the mesoderm (1).  This translates 
to humans as well; when human embryonic stem cells are exposed to BMP4, 
mesoderm differentiation is induced (13).  Indeed, both Activin A and BMP4 can 
induce MIXL1 expression in human embryonic stem cells (14-16), and Mix.1 is 
an intermediate for BMP4-mediated dorsal-ventral patterning in Xenopus (17).  
The promoter regions for both human MIXL1 and mouse Mixl1 contain multiple 
SMAD binding elements (12).   
 TGF-β ligands have also been implicated in the regulation of MIXL1 
expression.  TGF-β signaling can activate Mixl1 expression in mouse in 
collaboration with the transcription factor FoxH1 (18), and FoxH1 can collaborate 
2
with Gsc to suppresses Mixl1 expression (19).  MIXL1 may be transcriptionally 
regulated by the TGF-β superfamily of cytokines through TGF-β/BMP receptors 
to activate the SMAD family of transcription factors.   
  
3. MIXL1 in Hematopoiesis and Hematopoietic Neoplasms 
 While MIXL1 is well characterized in the role of mesoderm formation 
during embryogenesis, its roles in post natal homeostasis have gone 
uncharacterized.  In adults, MIXL1 is expressed in hematopoietic progenitor cells 
(2).  This has implicated a potential role of MIXL1 in hematopoiesis, and indeed 
loss of Mixl1 in mouse embryonic stem cells leads to significant hematopoietic 
defects (20).  Additionally, MIXL1 is highly expressed in Hodgkin’s, Burkitt’s and 
Diffuse Large B Cell Lymphoma (21), and leukemia and lymphoma cell lines (2), 
implying a role in the pathogenesis of hematopoietic neoplasms, leukemia and 
lymphoma progression.   
In mouse, enforced expression of Mixl1 in hematopoietic stem cells 
resulted in a transplantable acute myeloid leukemia (AML) with a 200 day latency 
in 100% of mice (22).  Furthermore, enforced expression of Mixl1 in 
hematopoietic stem cells conferred abnormal self-renewal potential to 
granulocytic precursors  (23).  Additionally, viral integration into the Mixl1 locus in 
mice was identified as a potential collaborator to p27Kip1 loss in inducing T-cell 
leukemia (24).  MIXL1 therefore may play a significant role in a subset of 
hematopoietic neoplasms. 
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4. Homeobox genes in Acute Myeloid Leukemia 
A large body of evidence implicates the deregulation of homeobox genes 
is important for the progression of AML and is often associated with the poorer 
outcomes.  Aberrant expression of both type I clustered homeobox-containing 
proteins, including HOXA9 and HOXB3 (25-27), and type II non-clustered 
homeobox genes, including HLX and CDX2, have been reported (28-32).  Non-
random chromosomal translocations resulting in homeobox-containing proteins 
are also a common occurrence in AML, and further underscore the importance 
and leukemogenic potential of aberrant expression of homeobox proteins (33, 
34).  While homeobox-containing proteins expression is tightly controlled and 
each protein is only expressed at a restricted stage of differentiation during 
normal hematopoietic maturation, homeobox-containing proteins are 
constitutively expressed in AML.  A recurrent functional consequence of all 
homeobox genes over expression is self-renewal, a limiting step in AML 
pathogenesis (35).  While many homeobox genes identified are strongly 
associated with AML are considered markers of poor prognosis, whether there is 
overlap in expression between many of the identified homeobox proteins in AML 
is unknown.  Similar hematopoietic-relevant homeobox genes may have a similar 
function in transformation of the remaining cases. 
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5. NF-κB Pathway in Leukemia and Lymphoma 
 The NF-κB family includes transcription factors that regulate stress 
response, proliferation, apoptosis, cell growth, and immune response.  Each 
active NF-κB complex consists of a dimer between a NF-κB/REL protein 
including a transactivation domain (RELA, RELB, and c-REL), and one that does 
not (NFκB1 or NFκB2).   Of the five NFkb genes, c-REL is a proto-oncogene as 
the chicken reticuloendotheliosis viral ortholog v-rel   transforms hematopoietic 
cells.  (36).   
 The activation of NF-κB complexes has been implicated in both 
hematopoietic progenitor self-renewal and leukemia and lymphoma progression.  
In hematopoietic stem cell transplantation, knockout of both NF-κB2 and RelB 
impairs engraftment due to increased self-renewal capacity (37).  In Diffuse large 
B-cell lymphoma, NF-κB complexes are commonly activated, and elevated c-
REL expression in the germinal center subtype correlates with poor survival (38).  
NF-κB complexes are also constitutively active in leukemic progenitor cells and in 
acute myeloid leukemia (39). 
 One of the functional consequences of NF-κB activation is the 
transcriptional activation of the BCL2 (B-cell CLL/lymphoma 2) family.  The BCL2 
family consists of three proteins (BCL2, BCL2A1, BCL2L1), all of which function 
as anti-apoptotic factors by inhibiting the release of Cytochrome C release during 
caspase-mediated apoptosis.  Overexpression or amplification of BCL2 are 
common pro-survival modifications in cancer, and  recurrent chromosomal 
5
translocations resulting in  constitutive expression of  BCL2  is common  of 
diffuse large B-cell lymphoma (40). 
  
6. Clarifying the role of MIXL1 in Acute Myeloid leukemia 
 While MIXL1 has been implicated in acute myeloid leukemia, little is 
known about its overall role in leukemia.  I hypothesize that MIXL1 is regulated 
by the BMP4 pathway in hematopoiesis and leukemia cell lines to promote 
proliferation through transcriptional activation of downstream targets. In the 
following pages, I identify a novel direct transcriptional target of MIXL1 in 
leukemic cell lines, the proto-oncogene c-REL, by chromatin immunoprecipitation 
(ChIP) and mRNA expression analysis.  I also identify thatMIXL1 is induced in 
normal hematopoietic stem progenitors by BMP4.  Consequently, BMP pathway 
inhibitor LDN-193189 is sufficient to impair growth in MIXL1-expressing AML 
lines in vitro.  
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Chapter 2. Materials and Methods 
1. Cell Culture 
 AML cell lines U937, HL-60, OCI-AML2, ML3, and chronic myeloid 
leukemia cell line K562, were grown under conditions of 5% CO2 and 37C in 
RPMI 1640 with 10% FBS.  AML cell line KG-1 was grown in RPMI 1640 with 
20% FBS. Human embryonic cell line HEK-293T was grown in DMEM with 10% 
FBS under 5% CO2 and 37C. 
Human cord blood hematopoietic stem progenitors cells (CD34)+ from 
three subjects denoted 47, 51, and 60,  were provided by Drs. Lisa St. John and 
Jeffrey Molldrem. 
  
2. Establishment of Overexpression and Knockdown Cell Lines 
 Inducible expression cell lines for FLAG-HA-tagged MIXL1 were 
previously established using U937T cells containing pTET-VP16PURO by 
electroporation following a protocol  previously described by the lab (41).  Clones 
used are denoted U937.1MIXL and U937.2MIXL, while an empty vector control is 
denoted U937.Control. 
 Lentiviral Production: Viral particles were generated  in HEK-293T by 
transient transfection of the lentiviral expression construct, envelope construct 
pCMV-VSV-G, encoding the viral envelop protein VSV-G, and a gag-pol-
encoding construct, at a ratio of 2:1:1 respectively.  Lentiviral constructs were 
purchased from OpenBiosystems (Pittsburg, PA) and designated as such: MIXL1 
KD1 = TRCN0000019155, MIXL KD2 = TRCN0000019156, and c-REL 
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Expression = ccsbBroad304_11094.  The  cells  were incubated for 48 hours at 
37ºC before harvesting the media containing   viral particles.  Viral particles were 
purified by passage through a 45 µm filter, and stored in -80⁰C until use. 
 Lentiviral transductions were performed by resuspending 2x105 cells in 1 
ml of virus-containing conditioned medium with 8 µg/ml polybrene, and then 
incubated at 37⁰C for 24 hours.  After the incubation, the cells were pelleted by 
centrifugation and resuspended in the growth medium.  Growth assay and 
expression experiments were performed 48 hours after transduction. 
  
3. Chromatin Immunoprecipitation 
  Chromatin Immunoprecipitation was based on the one used by Chadee et 
al (42), with the following modifications.   For each U937 cell line, a total of 108 
cells were cross-linked with 1% formaldehyde in growth media at 37ºC for 20 
minutes.  Cells were harvested by centrifugation at 3000 RPM for 10 minutes, 
and resuspended in 500 μL RIPA lysis buffer. After 10 minutes on ice, the cells 
were sonicated 20 times at 4-5 watts for 20 seconds, with a rest time of 40 
seconds between each sonication.  The samples were then centrifuged for 5 
minutes at 4ºC and precleared with 20 μL A/G agarose slurry for 1 hour at 4ºC.  
Two aliquots from each lysate was processed as follows  (i) Flag-IP: 240 μL of 
the lysate, 250 μL lysis buffer, and 8.4 μg mouse anti-flag antibody (anti-Flag-M2, 
Sigma), (ii) IgG-IP  240 μL of the lysate, 250 μL lysis buffer, and 8.4 μg mouse 
IgG.  The samples were incubated overnight at 4ºC with rotation, and then 
incubated for an additional hour with 20 μL A/G agarose slurry.  The agarose 
8
beads were recovered by centrifugation and washed for 15 minutes each in: 
RIPA lysis buffer, high salt RIPA buffer, lithium chloride RIPA buffer, and finally 
TE  prior to Proteinase K and RNAse  treatment at 37ºC overnight.  The samples 
were incubated for 6 hours at 65ºC to reverse crosslinking.  DNA was 
precipitated overnight at -20ºC in 75% ethanol, and then washed twice in 75% 
ethanol.  For each sample  DNA from a 20 μL aliquot of the pre immune 
precipitation lysate diluted with 180 μL TE buffer served as another control for 
target amplification. The DNAs were resuspended in 50 μL ddH2O and the Pre-
IP sample was then diluted with 450 μL of ddH2O.    
50 ng each of immuno precipitated DNAs from (1)  U937 Control IgG-IP, 
(2) U937 Control Flag-IP, (3) U937 1MIXL Flag-IP, and (4) U937 2MIXL-IP were 
used to construct libraries by the Sequencing and Microarray Facility (SMF) at 
MD Anderson Cancer center using the Beckman SPRIworks system. Illumina 
analysis pipeline GAPipeline-1.5.0 was used for base calling and alignment to 
human genome.  Peak calling was done by MACS v1.3.7.1 at pvalue<=1e-5.  
Peaks were identified against the human genome (UCSC assembly hg18, 
NCBI36) using genome model-based analysis of ChIP-Seq [MACS](43), and 
were generated by normalizing to the two control samples in three combinations: 
Flag-1MIXL to IgG-Control and Flag-Control, Flag-2MIXL to IgG-Control and 
Flag-Control, and Flag-1MIXL and Flag-2MIXL combined to IgG-Control and 
Flag-Control.  The primary dataset used for analysis was overlapping peaks in all 
three analyses. The combined dataset was tested for predicted Paired-Q9 
binding motifs(8) using Motif alignment and Search Tool [MAST](44), and 
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enriched motifs were identified using Multiple EM for Motif Elicitation 
[MEME](45). 
Peaks were allocated to genes within a 25kb region, designated as 
follows:  upstream – 5 to 25 kb upstream of the transcription start site, promoter – 
0 to 5 kb upstream of the transcription start site, body – between the transcription 
start and end, TSE – 0 to 5 kb downstream of the transcriptional end, 
downstream – 5 to 25 kb downstream of the transcriptional end, and distant – not 
allocated to a gene.   
 ChIP-qPCR confirmation was performed by SYBR green quantitative PCR 
using primersets for each peak region identified and an exonic c-REL region 
primer set for control, as listed in Table 1.  For ChIP-qPCR against endogenous 
proteins, 5 μg anti-MIXL1-N and anti-MIXL1-C antibodies (2) and anti-MZF1 (sc-
66991, Santa Cruz Biotechnologies, Dallas, TX) were used for 
immunoprecipitation. 
 
4. Global Expression Analysis 
The original microarray analysis was performed previously by Dr. Hong 
Liang.  To identify potential targets of the MIXL1 transcription factor, Dr. Liang 
performed global expression profiling analysis on MIXL1-expressing cells by 
microarray.  The cell lines 1MIXL and Control were cultured without TET for 24 
hours at 5X104 cells/mL.  RNA was extracted from 5x106 cells by RNEASY 
Minikit (QIAGEN, Valencia, CA).  Extracted RNA was hybridized against a 
Human Genome Affymetrix HG133A Microarray (Affymetrix, Santa Clara, CA). 
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For analysis, dChip analyzer software (46) was used, normalizing the 
1MIXL dataset to the Control dataset, and gene expression models were 
obtained through PM (Perfect Model)-only approach.  Differentially expressed 
genes were defined as genes in which the difference between the detected 
expression levels was at least 100, and the ratio was at least 1.2. 
 The networks analyses were generated through the use of Ingenuity 
Pathway Analysis (Ingenuity Systems, www.ingenuity.com). 
 
5. RT-QPCR 
 RNA was purified using RNeasy Mini Kit from 5x106 cells for each line.  
200 ng from each sample was then reverse transcribed and diluted 10-fold.  The 
samples were assayed by qPCR in triplicate using Taqman primers obtained 
from Applied Biosystems/Life Technologies (Carlsbad, CA) and Integrated DNA 
Technologies (Coralville, Iowa), as denoted in Table 2, and then quantified by 
delta-delta-CT method. 
 For CD34+ cells, RNA was harvested in triplicate from ~2500 cells by 
RNeasy Micro Kit + (QIAGEN, Valencia, CA) 2 hours after addition of either 50 
ng/ml BMP4 (314-BP, R&D Systems, Minneapolis, MN) or 2 ng/ml TGF-β1 
(Sigma-Aldrich) in X Vivo-15 medium (Lonza, Allendale, NJ), then 100 ng from 
each sample was reverse transcribed and assayed. 
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Table 1.  Primer sets used for ChIP-qPCR.  Listed are the primers used for 
quantitative PCR analysis of the Chromatin Immunoprecipitation techniques.  
Each primer set is will generate a 100-200 bp product encoded near the center of 
the ChIP-Seq identified gene locus peak, with exception of Rel-Int-F/-R, which 
covers a 100-200 bp region internal of the REL gene locus not enriched in the 
ChIP-Seq analysis. 
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Primers used ChIP-qPCR 
Rel-Int-F 5-TTACCAGGATTTTGGCAAGG-3 
Rel-Int-R 5-CAGGCAGTTTGGGGATAAGA-3 
Rel-F 5-GGAACCACCTCTCGAAAACC-3 
Rel-R 5-TCCAGGTTGTTCTTCCGAGT-3 
EIF1-F 5-TGACTCCGTGGGTAGTAGGG-3 
EIF1-R 5-CCTTCTTGACCCTGTTGCAT-3 
SLC39A13-F 5-CCTGAGGTTCCCAGTGAAAA-3 
SLC39A13-R 5-GAGGACTACTGTGCGCTCCT-3 
SMYD5-F 5-TTCCCCCTTTCATGACTCTG-3 
SMYD5-R 5-CTCAGCTCAGTCCCCAAGAG-3 
ZP3-F 5-ACCTCAGCCTCCCCAGTAGT-3 
ZP3-R 5-TTGATCCAAAAGCAGCTGAA-3 
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Table 2.  Probe-sets used for RT-QPCR analysis.  Listed are the probes used 
for reverse transcription-coupled quantitative PCR for each of the respective 
genes.  Probes for MIXL1, REL, BCL2L1, and BCL2A1 were supplied by Applied 
Biosystems (Carlsbad, CA), while probes for APBB2, IL18R1, and PCGF2 were 
customized and ordered from Integrated Integrated DNA Technologies 
(Coralville, Iowa), to be fully compatible with TaqMan analysis.  
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Probes used for qPCR 
MIXL1 Hs00968440_m1 TaqMan, Applied Biosystems 
REL Hs00231279_m1 TaqMan, Applied Biosystems 
BCL2L1 Hs99999146_m1 TaqMan, Applied Biosystems 
BCL2A1 Hs00187845_m1 TaqMan, Applied Biosystems 
EGR1 Hs00152928_m1 TaqMan, Applied Biosystems 
APBB2 
Probe   5-CTCCCCAAATCCCGACTGTGTCT-3 
5' 6-FAM, 3' Iowa Black FQ 
Primer1 5-GATGGGTAGAGATGGCAGAAG-3 
Primer2 5-GGATCAGGTACATGTCTTTCCC-3 
Integrated DNA Technologies 
IL18R1 
Probe   5-CCTCCAGGCACTACATCCCTTTCAA-3 
5' 6-FAM, 3' Iowa Black FQ 
Primer1 5-CACCTTTGCTGTGGAGATTTTG-3 
Primer2 5-TCTTCGGCTTTTCTCTATCAGTG-3 
Integrated DNA Technologies 
PCGF2 
Probe 5-TGGACATCGCCTACATCTACCCCT-3 
5' 6-FAM, 3' Iowa Black FQ 
Primer1 5-GACGAGCCACTGAAGGAATAC-3 
Primer2 5-GCTGGACACGGTACTTGAG-3 
Integrated DNA Technologies 
  
15
6. Co-Immunoprecipitation 
 107 cells of U937-1MIXL were lysed with 1 ml ice-cold RIPA buffer 
(150 mM NaCl, 1.0%. NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris 
(pH 7.5), 5 µg/ml leupeptin, 8 µg/ml aprotinin, 1 mM PMSF, 0.7 µg/ml pepstatin A 
and 1 mM EDTA (pH 8.0)).  900 µl of the lysate was precleared by incubation with 
protein A/G-agarose beads for 1 hour at 4ºC. 5 µg M2 anti-flag monoclonal 
antibody and 5 µg mouse IgG antibody were each added to separate aliquots of 
450 µl cleared lysate, and incubated for 2 hours at 4ºC.  20 µl of protein G-
agarose beads was added to the immune complexes and incubated for 1 hour at 
4°C. After four washes with NET-N buffer (100 mM NaCl, 1 mM EDTA (pH 8.0), 
20 mM Tris (pH 8.0), 0.2% NP-40, 5 µg/ml leupeptin, 8 µg/ml aprotinin, 
1 mM PMSF, 0.7 µg/ml pepstatin A), the precipitated proteins were eluted in 20 µl 
of 2  SDS loading buffer (100 mM Tris (pH 6.8), 200 mM DTT, 4% SDS, 0.2% 
bromophenol blue, 20% glycerol) and then resolved by 10% NuPAGE gel 
(Invitrogen, Carlsbad, CA). 
 
7.  Immunoblotting 
 Cells were lysed in Whole Cell lysis buffer (20 mM Tris, 250 mM NaCl, 2 
mM EDTA, 1% Triton X-100, 1 mM DTT, 2 µg/ml Aprotinin, 2 µg/ml Leupeptin, 2 
µg/ml Pepstatin A, 1 mM NaVO3, 1 mM PMSF), then denatured in 4x SDS buffer 
at 90ºC for 10 minutes, then resolved on 10% NuPAGE gel (Life Technologies) 
using MOPS buffer, and transferred to a PVDF membrane (GE Healthcare, 
Pittsburgh, PA). 
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 Membranes were first blocked by incubation in TBS-T (50 mM Tris, 150 
mM NaCl, and 0.05% Tween 20 adjusted to pH 7.6) with 5% milk for one hour, 
after which they were washed in TBS-T two times for two minutes.  The 
membrane was then incubated with the first antibody for 2 hours 2% milk TBS-T 
at room temperature then washed in TBS-T two times for 5 minutes, then once 
for 15 minutes.  The blot was then incubated with the secondary antibody in 2% 
milk TBS-T for 1 hour, followed by another round of washes in TBS-T.  Blots 
were visualized using Amersham ECL western blotting detection reagent (GE 
Healthcare) with 5 minutes of film exposure. 
 Primary antibodies used were anti-MIXL1-N at 1:1500, MZF1 (sc-66991, 
Santa Cruz Technologies, Dallas, TX) at 1:100, and beta-actin (Sigma Aldrich) at 
1:5,000.  The secondary antibodies used were anti-rabbit-HRP (GE Healthcare) 
at 1:10,000 for the majority of primaries and anti-mouse-HRP (GE Healthcare) at 
1:7,000 for the beta-actin primary antibody. 
  
8. Luciferase Reporter Assay 
 Luciferase constructs were generated by PCR amplification of segments 
of the c-REL peak region identified by ChIP-Seq.  Promoter segments were 
amplified from genomic DNA extracted from human placenta with the primers 
listed in Table 3 and sub-cloned into the pBV-Luc vector between Mlu1 and 
EcoR1 sites.  Each luciferase reporter vector insert was then confirmed by 
sequencing.  293T cells were transfected with 200 ng of expression vector, 200 
ng of luciferase vector, and 0.2 ng Renilla Luciferase vector by Lipofectamine 
17
  
 
 
 
Table 3.  Primers used for REL Promoter Luciferase construct construction.  
Listed are the primer sets used to generate the REL promoter region inserts for 
construction of p-BV-Luc-based luciferase vectors for use in the luciferase 
reporter assay.  Each forward primer contains a Mlu1 target sequence and each 
reverse primer contains an EcoR1 target sequence for restriction digest.  Primers 
were used in pairs.  First set: Rel-R-EcoR1 paired with Rel-FM-130, Rel-FM-500, 
Rel-FM-700, and Rel-FM-944, with the Forward primer name denoting length of 
product.  Second set: Rel-FM-700 paired with Rel-RE-150, Rel-RE-200, Rel-RE-
300, and Rel-RE-580, with the Reverse primer pair denoting length of product. 
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Primers used for Luciferase Reporter Construction 
Rel-R-EcoR1 5-ctgt-gaattc-CGCAGTCAGTCAGTCAGGAG-3 
Rel-FM-130 5-ctgt-acgcgt-AGAATTCAGGGGTTGGGAAG-3 
Rel-FM-500 5-ctgt-acgcgt-GGAAGAACAACCTGGAGGAG-3 
Rel-FM-700 5-ctgt-acgcgt-GAACCACCTCTCGAAAACC-3 
Rel-FM-944 5-ctgt-acgcgt-GGAGCTTTGGAGTCAGACAA-3 
Rel-RE-150 5-ctgt-gaattc-CAGGTTGTTCTTCCGAGT-3 
Rel-RE-200 5-ctgt-gaattc-GGCTAGCAGCGTGAGAAGG-3 
Rel-RE-300 5-ctgt-gaattc-GACGCAGCAACCCTCACC-3 
Rel-RE-580 5-ctgt-gaattc-AACCCCTGAATTCTTGCAC-3 
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(Invitrogen, Grand Island, NY).  The activity was then tested by Dual Luciferase 
Reporter Assay System (Promega, Madison, WI) 48 hours post-transfection. 
 
9. MTS Assay 
 The growth assay for comparison of knockdown cell lines were performed 
by plating 3x104 cells/well for each line into a 96-well plate in triplicate, then 
testing the culture growth by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay every 24 hours 
of incubation.  
 For comparative analysis of the effects of doxorubicin on U937 MIXL1-
overexpressing lines, the three clones (Control, 1MIXL, and 2MIXL) were seeded 
to a 96-well plate at a density of 3x104 cells/well.  Doxorubicin (Sigma-Aldrich, St. 
Louis, MO) was added to each well at 0 – 2 µM in triplicates, for 24 hours before 
MTS treatment. 
 To measure survival response to high concentrations of LDN-193189, 
each cell line was plated at 3x104 cells/well on 96-well plates and treated with 
either 3 µM LDN-193189 (Cellagen, San Diego, CA) or the equivalent 
concentration of DMSO in triplicate.  Each line was then tested by MTS assay 
immediately, then again every 24 hours. 
 For the dose response experiments for LDN-193189, each line was plated 
at 3x103x104 cells/well on 96-well plates and treated with 0 – 0.7 µM LDN-
193189 in triplicate.  The cells were then incubated for 4 days, with additional 
treatments of 0 – 0.7 µM LDN-193189, before being tested by MTS assay. 
20
 The MTS assay was performed by the CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay kit (Promega) with an incubation time of 1 
hour. 
 
10. Analysis and Data mining 
 TCGA AML database (47) was accessed and analyzed through the 
cBioPortal (48, 49) for cases either with a mutation, copy-number alteration, or 
expression change of 2-fold or over (1.0 threshold). 
 Identification of transcription factor binding motifs in the c-REL promoter 
was performed using TFSearch. (50)  
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Chapter 3. Results 
1. Characterization of AML cell lines with overexpression of MIXL1 
 To identify the role of MIXL1 in AML, I used FLAG-HA-tagged MIXL1 
inducible expression cell lines established in U937, a hystiocytic lymphoma, 
previously created in the lab, denoted U937.1MIXL and U937.2MIXL with an 
empty vector control line U937.Control.  While these clones were initially 
established with MIXL1 expression inducible by tetracycline withdrawal, after 
multiple passaging both clones exhibited enforced MIXL1 expression regardless 
of tetracycline induction, and were subsequently treated as overexpression lines.   
To determine if the levels of MIXL1 protein in the overexpression lines was 
comparable to endogenous protein levels in leukemia, I compared the protein 
levels of 1MIXL and 2MIXL to that of three AML lines, the high-expressing KG1 
and ML3 and low-expressing HL60, where MIXL1 protein levels had already 
been tested (2), the previously untested AML OCI-AML2, and the CML line K562 
(Figure 1).  Protein expression in 1MIXL and 2MIXL was comparable to that of 
the expressing cell lines K562, KG1, ML3, and OCI-AML2, while U937.Control 
and HL60 had no detectable levels of MIXL1. 
  To test if MIXL1 infers a survival advantage in leukemic cell lines, I 
performed a MTS assay comparing the survival of the U937 subclones under 24 
hour exposure to 0 – 2 µM of the leukemia chemotherapy drug doxorubicin 
(Figure 2).  After 24 hours of treatment, doxorubicin had a LD50 of 0.25 µM for the 
U937.Control line and 0.75 µM for 1MIXL and 2MIXL, with only the Control line 
nearly completely eliminated at the 1.75 µM concentration of doxorubicin.  
22
  
 
 
 
 
 
 
Figure 1.  Stable transfectants of U937 cells express MIXL1 at levels similar 
to endogenous protein in AML cell lines.   MIXL1 detected by probing 30ug 
whole cell lysates resolved on SDS-PAGE, transferred to PVDF membrane,  with 
rabbit antibodies against N–terminal epitope of MIXL1  and  β actin  for loading 
control.  
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Figure 2. MIXL1 expression reduces sensitivity of U937 cells to 
doxorubicin.  The cell lines were treated with 0 µM to 1.75 µM Doxorubicin on 
Day 0. Cell survival was measured at 24 hours by MTS assay.  Absorbance of 
untreated cells was normalized to 1.  Relative viability at varying concentrations 
of doxorubicin is denoted. 
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 2. ChIP-Seq analysis of MIXL1 overexpression lines to identify 
transcriptional targets 
 As few transcriptional targets for MIXL1 in hematopoiesis have been 
identified, I performed ChIP-Seq in our overexpression clones to identify 
transcriptional targets of MIXL1.  Flag-HA-MIXL1 and bound DNA segments 
were immunoprecipitated from both 1MIXL and 2MIXL by FLAG antibodies, 
alongside two control samples of FLAG-IP in U937.Control with no expected 
target, and IgG-IP in U937.Control.  The sequenced samples were then aligned 
to the genome and analyzed in different pairwise combinations by Dr. Yue Lu 
and Dr. Shoudan Liang:  1MIXL-Flag normalized to Control-Flag and Control-
IgG, 2MIXL-Flag normalized to Control-Flag and Control-IgG, 1MIXL-Flag and 
2MIXL-Flag combined then normalized to Control-Flag and Control-IgG.  Each of 
these sets identified over 1500 peaks, though only a small subset containing 179 
peaks was present in all four groups (Figure 3).  The overlap subset shared by all 
three groups was isolated and used in further studies (Appendix). 
As a homeobox transcription factor, we expected MIXL1 to primarily 
interact with promoter regions of gene loci.  To determine if this was the case, 
Yue Lu and Dr. Shoudan Liang identified where each peak in the 179 peak set 
was in relation to its nearest gene loci (Appendix and Figure 4).  Out of the 179 
peaks, 64% of the peaks localized to the promoter region (within 5 kb upstream 
of the transcription start site), 8% were localized to transcribed gene regions, 4% 
were between 25 kb and 5 kb upstream of the transcription start site, 1% were 
27
  
 
 
 
 
Figure 3.  Multiple analyses of MIXL1-ChIP-Seq identify 179 high-quality 
peaks.  Venn diagram of all the peaks identified using three different analyses of 
the two experimental (Flag immunoprecipitation in U937 1MIXL or 2MIXL) and 
two negative control (Flag or IgG immunoprecipitation in U937 Control) : 1MIXL 
vs Controls, 2MIXL vs Controls and 1MIXL+2MIXL vs Controls.  Out of the peaks 
identified, 179 peaks were significantly enriched in all sets. 
This figure was generated as part of the statistical analysis performed by Dr. Yue 
Lu and Dr. Shoudan Liang for ChIP-seq. 
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Figure 4.  The majority of peaks for MIXL1 identified by ChIP-Seq localize to 
the Promoter region.  Pie chart depicting the localization of MIXL1 to human 
genome. Peaks were classified based on distance to nearest transcribed gene 
locus, using the following criteria:  upstream – 5 to 25 kb upstream of the 
transcription start site, promoter – 0 to 5 kb upstream of the transcription start 
site, body – between the transcription start and end, TSE – 0 to 5 kb downstream 
of the transcriptional end, downstream – 5 to 25 kb downstream of the 
transcriptional end, and distant – not allocated to a gene. Note that  majority of 
peaks (67%) localized to gene promoters.     
30
  
UPSTREAM
4%
PROMOTER
64%
BODY
8%
TSE
1%
DOWNSTREAM
3%
DISTANT
20%
31
within 5 kb of the transcription sequence end, and 3% were between 25 kb and 5 
kb of the transcription sequence end.  20% of the peaks were classified as not 
being within 25 kb of any known genes. 
As stated in the introduction, MIXL1 is a paired type homeobox with a 
previously characterized predicted motif (8).  To determine if this motif is how 
MIXL1 is bound to the identified motif locations, Dr. Yue Lu and Dr. Shoudan 
Liang analyzed the 179 peak set (Appendix) and a comparable randomized DNA 
fragment set for two different variants of the motif using the Motif alignment and 
Search Tool [MAST] (44) (Figure 5).  Neither motif was significantly over-
represented in the 179 peak set compared to the random set; therefore, the 
expected motif for MIXL1 is not enriched in our peak set.  To characterize what 
motifs were enriched in our peaks, Dr. Yue Lu and Dr. Shoudan Liang next 
performed Multiple EM for Motif Elicitation [MEME] (45) for the sequences 200 
base-pairs around each peak summit.  The two highest peak motifs (Figure 6) 
are CG-rich and show no similarity to the AT-rich predicted homeobox motifs 
(TAAT); instead, they are more similar to zinc finger motifs. 
To confirm the peak regions enriched in SET4 of the ChIP-seq analysis, I 
reanalyzed five of those regions, peaks near EIF1, c-REL, SLC39A13, SMYD5, 
and ZP3, by ChIP-qPCR in U937.Control, 1MIXL and 2MIXL by ChIP-qPCR 
using the Flag-antibody for immunoprecipitation (Figure 7).  While each peak was 
enriched by ChIP-qPCR, only EIF1, SLC9A13, and SMYD5 had the scale of 
enrichment over the control samples that were seen in the ChIP-seq.  This may 
be due to variability between the techniques.  
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Figure 5. Predicted MIXL1 motifs are not enriched in U937 overexpression 
MIXL1 ChIP-seq Peaks.  Motif1 and Motif2 were previously characterized 
putative MIXL binding motifs, and were searched against the stringent set of 
peaks (Appendix) at various distances (1000bp, 500bp, 200bp, or 100bp as 
listed) from the peak apex (top lines) and from the center of randomized 
sequences of the same length (bottom lines) , at either a p-value of 1e-4, 5e-4, or 
1e-3.   In all cases, the likelihood of finding the MIXL1 binding motif was either not 
statistically significantly different or even lower than the likelihood of identifying 
the motif in randomized sequences, therefore the MIXL1 binding motif is not 
enriched in this dataset. 
This figure was generated as part of the statistical analysis performed by Dr. Yue 
Lu and Dr. Shoudan Liang for ChIP-seq. 
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Motif1 
 
 
 
Motif2 
 
 
Motif1 (179 peaks)   Motif2  (179 peaks) 
pvalue  1e-4 5e-4 1e-3  pvalue  1e-4 5e-4 1e-3 
1000bp 3 31 59  1000bp 4 13 27 
  4.97 44.6 77.75    3 17.57 37.06 
500bp 1 9 18  500bp 2 3 9 
  1.65 18.2 35.65    0.98 6.49 14.55 
200bp 0 2 3  200bp 0 1 2 
  0.43 5.76 12.06    0.32 1.72 4.57 
100bp 0 0 1  100bp 0 0 0 
  0.18 2.75 5.62    0.11 0.91 2.1 
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Figure 6.  The most commonly occurring motifs in the ChIP-seq peaks are 
Zinc-Finger binding motifs.  Motif1 and Motif2 were the two most statistically 
significant common motifs generated using the Multiple EM for Motif Elicitation 
[MEME] against the peak regions identified in the ChIP-seq analysis (Appendix).  
Both motifs are C/G-heavy regions of similarity to known zinc finger motifs.   
This figure was generated as part of the statistical analysis performed by Dr. Yue 
Lu and Dr. Shoudan Liang for ChIP-seq. 
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MOTIF 1 width = 15 sites = 65 E-value = 1.1e-027 
 
 
MOTIF 2 width = 15 sites = 112 E-value = 3.6e-015 
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Figure 7.  ChIP-qPCR analysis of selected gene-associated peaks confirms 
enrichment.  ChIP of 5 candidate peaks with FLAG antibodies identified by 
ChIP-Seq (EIF1, c-REL, SLC39A13, SMYD5, ZP3) showed specific MIXL1 
binding both 1MIXL and 2MIXL clonal ChIP with normal mouse IgG served us 
control.  Error bars represent standard deviation between triplicates.  * denotes p 
value <0.05.  The chart below is the ChIP-seq results for the constrained (179-
peak) dataset for each of the peaks tested, for comparison.  
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ChIP-Seq Results for selected Peaks 
Gene Peak Location Enrichment Proximity to Gene 
EIF1 chr17:37097849-37099490 7.55 promoter 
REL chr2:60961441-60962652 9.79 promoter 
SLC39A13 chr11:47385814-47387193 6.87 promoter 
SMYD5 chr2:73293129-73293533 7.38 upstream 
ZP3 chr7:75905120-75905486 20.74 body 
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 3. Global Expression Profiling of MIXL1 overexpression to confirm 
transcriptional targets 
 To better identify direct transcriptional targets of MIXL1, I took a previous 
global expression profiling experiment performed in the lab on U937.Control and 
1MIXL using the U133 Plus 2.0 microarray by Dr. Hong Liang and reanalyzed it.   
To confirm the microarray analysis, a small subset of genes was tested by RT-
qPCR in U937.Control 1MIXL and 2MIXL (Figure 8).  While the expression of 
APBB2 and EGR1 were comparable between both methods at approximately -2-
fold and +2-fold change, respectively, IL18R1 expression was significantly higher 
in 1MIXL by qPCR at 3.5-fold in comparison to the 2.6 identified by microarray.  
Of specific note is c-REL, a gene also identified by ChIP-seq as a putative MIXL1 
transcriptional target, where both methods found a 1.66-fold increase in 1MIXL,  
and interestingly 2MIXL1 expressed 3.5-fold over U937.Control by qPCR. 
 
4. c-REL as a transcriptional target of MIXL1 
 Since c-REL was identified as a putative transcriptional target of MIXL1 by 
both ChIP-Seq and global expression profiling, I decided to get a broader look at 
the expression of the overall NF-κB pathway (Figure 9).  In the NF-κB pathway, 
NFκB1 or NFκB2 herterodimerize with RELA, RELB, or c-REL to transcriptionally 
regulate downstream targets, with the most common and best studied dimer pair 
being the RELA-NFκB1 dimer.  One of the common transcriptional targets of the 
NF-κB dimers is the anti-apoptotic BCL2 family (BCL2, BCL2L1, and BCL2A1).  
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Figure 8. RT-qPCR confirms change of expression in selected genes as 
identified by Microarray.  Quantitative RT-PCR confirms expression changes of 
selected genes identified by global expression profiling.  Quantitative RT-PCR 
showing differences in gene expression between U937 control, 1MIXL and 
2MIXL.  Transcript levels were normalized to 18srRNA.  Error bars represent 
standard deviation between triplicates. * denotes p value <0.05. The chart below 
is the Micorarray results for the 5 genes tested, for comparison.   
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Microarray Results for selected genes 
probe set gene Accession EntrezGene Fold Change 
216747_at APBB2 AK024871 323 -2.45 
201694_s_at EGR1 NM_001964 1958 2.78 
206618_at IL18R1 NM_003855 8809 2.63 
240752_at PCGF2 AW510760 7703 5.65 
206035_at REL NM_002908 5966 1.66 
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Figure 9. The NF-κB pathway is regulated by MIXL1.  The NF-κB pathway is 
regulated by MIXL1.  Output from HG133A affymetrix microarray expression 
profiling was analyzed by Ingenuity Pathway analysis software (IPA).  Green 
denotes decreased expression and red denotes increased expression relative to 
U937.control.  
42
  
 
  
 
43
The activity of these NF-κB dimers can be inhibited by binding with IκB family 
proteins (NFKBIA/B/E), which block nuclear localization of the dimer.  In the 
global expression profile under MIXL1 overexpression in 1MIXL, all these genes 
are differentially regulated: the IκB family members and both components of the 
abundant NF-κB dimer (RELA and NFκB1) are down-regulated, while the less 
abundant NF-κB members c-REL and RELB and the anti-apoptotic BCL2L1 and 
BCL2 are up-regulated.  The anti-apoptotic BCL2A1, however, was down-
regulated. 
 To confirm the change of expression characterized in the global 
expression profiling for c-REL, BCL2A1 and BCL2L1, I analyzed RNA expression 
levels by RT-qPCR between U937.Control, 1MIXL and 2MIXL (Figure 10).  
Expression of c-REL increased approximately 1.8-fold in 1MIXL and 3-fold in 
2MIXL, in agreement with the previous run (Figure 8); BCL2L1 expression 
increased approximately 2-fold in each line in confirmation with the microarray 
results, while BCL2A1 expression increased approximately 2-fold as well,   
raising  the possibility of a potential technical difference between the two assays. 
 While I have identified c-REL promoter region as a target for MIXL1, it is 
possible that the perceived interaction is either an artifact of the Flag antibody or 
unique to U937 cells.  To test both of these possibilities, I performed ChIP-qPCR 
on the  endogenous C-REL promoter in the AML cell line KG1 using both our N-
terminal and C-terminal MIXL1 antibodies (Figure 11).  In both cases, the c-REL 
promoter was enriched: 3-fold for MIXL-N and 2-fold for MIXL-C, while the 
internal  genomic locus was not. 
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Figure 10. MIXL1 expressing clones show enhanced transcript levels for c-
REL, BCL2A1, and BCL2L1.  Quantitative RT-PCR results showing the 
difference in expression between U937control, 1MIXL and 2MIXL for c-REL, 
BCL2A1, and BCL2L1.  Expression was normalized to 18srRNA transcript levels. 
Error bars represent standard deviation between triplicates. * denotes p value 
<0.05 
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Figure 11.  ChIP localizes endogenous MIXL1 to c-REL promoter in KG1 
cells.  Quantitative genomic PCR analysis shows specific enrichment of 
endogenous MIXL1 immunopreciptated with either N-terminal or C-terminal 
MIXL1 antibodies,on the c-REL promoter whereas an internal locus within the c-
REL gene showed no MIXL1 occupancy.  Error bars represent standard 
deviation between triplicates.  * denotes p value <0.05. 
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 5. MIXL1 knockdown in KG1 represses c-REL and BCL2A1/L1 expression 
 To confirm MIXL1 regulation of c-REL and its downstream targets, I 
knocked down MIXL1 expression by shRNA lentiviral transfection in the high-
MIXL1 expression AML cell line KG1, and then attempted to reverse the 
phenotypes by enforcing expression of c-REL. I first tested the expression of 
MIXL1, c-REL, BCL2A1, and BCL2L1 under knockdown of MIXL1 and enforced 
expression of c-REL by RT-qPCR (Figure 12).   Under MIXL1 knockdown, MIXL1 
expression is down to 0.25-fold, while expression of c-REL, BCL2A1, and 
BCL2L1 down to about 0.6-fold, 0.5-fold, and 0.7-fold, respectively.  With the 
enforced expression of c-REL, expression of c-REL, BCL2A1, and BCL2L1 
increase approximately 2-fold, regardless of MIXL1 expression level. 
 To identify if loss of MIXL1 affects the growth rate of KG1 cells, I assayed  
the knockdown lines over the course of four days for growth by MTS assay 
(Figure 13).  While the control shRNA cell line and REL-enforced expression line 
grew at a stable rate over 4 days, the knockdown lineages had lower cell counts 
than the starting count  at 24 hours before recovering to a stable growth rate by 
day four.   
 
6. MZF1 and MIXL1 interact with the c-REL promoter 
 From the ChIP-seq analysis, I have identified the c-REL promoter as a 
binding target for MIXL1; however the peak region identified is over 1000 base-
pairs long, and is lacking in putative MIXL1 motifs.  These details pose the 
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Figure 12.  Knockdown of MIXL1 decreased while enforced expression of c-
REL increased c-REL, BCL2A1, and BCL2L1 transcript levels.  MIXL1 
shRNA lentivirus, c-REL retrovirus were transduced into KG1 cells. RT-qPCR in 
triplicates was performed on RNAs isolated 48 hours after transduction. 
Expression was normalized to 18srRNA levels, and error bars represent standard 
deviation between triplicates.  * denotes p value <0.05 
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Figure 13. c-REL over expression rescues of  MIXL1 knockdown mediated 
growth arrest in KG1 cells.  Growth was measured by MTS assay every 24 
hours over a 4 day period in KG1 cells transduced with   MIXL1 shRNA lentivirus 
and c-REL retrovirus.  Absorbance was normalized to that of a non-transfected 
control sample. 
  
52
  
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0 1 2 3 4
A
dj
us
te
d 
A
bs
or
ba
nc
e 
(M
TS
)
Day
KG1 KG1 MIXL KD1
KG1 MIXL KD2 KG1 + REL
KG1 MIXL KD1 + REL KG1 MIXL KD2 + REL
53
question: what part of this region is required for MIXL1 interaction and what else 
is required for it?  To answer this question, I first tried to identify which region of 
the peak MIXL1 needs to regulate c-REL expression by performing a luciferase 
reporter assay with nested deletions of the c-REL promoter.  By subcloning 
genomic fragments of the c-REL promoter generated by PCR (Figure 14, 130 to 
944), I generated luciferase constructs in the backbone pBV-Luc. The luciferase 
constructs were then co-transfected into HEK293T cells with a MIXL1 expression 
construct, a homeoboxless truncated MIXL1 expression construct, or an empty 
expression vector; the cells were tested for luciferase activity.  Of these first sets, 
only the 700 base-pair and 944 base-pair promoters were significantly induced 
by full-length MIXL1.  To narrow down the region further, I took the N-terminus 
region of the 700 base-pair promoter insert and extracted progressively shorter 
segments of the promoter in it (Figure 14, 550 to 150).  The only promoter 
segment that was significantly induced by full-length MIXL1 was the 550 base-
pair segment. 
 To identify potential binding partners for MIXL1 that are required for c-REL 
transcriptional regulation, I searched the 550 base-pair region of the c-REL 
promoter for known transcription factor binding motifs (Figure 15).  The motifs 
identified included 2 NF-κB motifs, a RUNX1 motif, 2 Sp1 motifs, and 4 MZF1 
motifs.  As MZF1 (myeloid zinc finger 1) is a transcription factor associated with 
the myeloid lineage and implicated in myeloid leukemia (51, 52), it may be 
expressed in MIXL1 expressing cells and may in fact have a synergistic role.  To 
determine if MIXL1 and MZF1 are actually interacting, I performed co-
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Figure 14.  MIXL1 interacts with the center of the identified peak region of 
the REL promoter.  (Above) c-REL promoter peak region identified by ChIP-
Seq, as generated by UC Santa Cruz genome browser is shown.  The location 
and size of each promoter fragment used for the luciferase reporter assay  is 
displayed underneath.  (Below) MIXL1 binds to  a 550 bp region within the c-REL 
promoter.  Regions of the DNA depicted in 5A were cloned into the reporter 
vector pBV-Luc luciferase, transiently co-transfected into HEK293T  with MIXL1, 
MIXL1 Homeobox-less, or empty expression vector. Equal amount of  Renalia 
Luciferase co-transfected with the reporter constructs allowed normalization.  
Luciferase activity of each combination was tested after 48 hours in triplicate.  
Error bars represent standard deviation between triplicates. * denotes p value 
<0.05 
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Figure 15.  Known Transcription Factor Binding Motifs in the REL 
Promoter.  A visual representation of the location of identified transcription factor 
binding motifs by TFSearch in the 550 bp REL promoter identified by luciferase 
reporter assay.  Of note, the most prevalent motif in this region is the MZF1 zinc 
finger binding motif (marked in blue), which is present in four locations. 
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immunoprecipitation by anti-Flag antibodies in 1MIXL, using a mouse IgG as a 
control then blotted it with a MZF1 antibody (Figure 16).  The expected MZF1 
band (~82 kDa) was present in the 1MIXL lysate and Flag-immunoprecipitation 
but not the IgG-immunoprecipitation, implicating that MIXL1 and MZF1 may form 
a complex. 
 To determine if MZF1 binds to the c-REL promoter in the expected region, 
I performed ChIP-qPCR analysis using the c-REL promoter and intron primersets 
to probe MZF1-immunoprecipitated genomic DNA from cell line 1MIXL (Figure 
17). The promoter region was enriched approximately 2.5-fold in the MZF1-
immunoprecipitated fraction, while the intronic control region was not enriched. 
 
7. MIXL1 is preferentially induced   by BMP4 in  human CD34+ cord blood 
hematopoietic stem progenitor cell 
MIXL1 has previously been described as a transcriptional target of SMAD 
proteins (53)  through the canonical TGF-β and BMP signaling pathways.   To 
identify whether the TGF-β or BMP is the relavant ligand in hematopoiesis, I 
treated CD34+ hematopoietic progenitor cells with either 2 ng/ml of TGF-β1 or 50 
ng/ml BMP4, and tested the relative mRNA levels of MIXL1 after 2 hours (Figure 
18). BMP4 was able to significantly activate MIXL1 expression relative to the un-
induced CD34+ samples by about 2-fold, while TGF-β had no effect on MIXL1 
expression.  This implicates BMP4 to be a preferred regulator of MIXL1 
expression in hematopoiesis. 
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Figure 16.  MZF1 is identified by co-immunoprecipitation of Flag-tagged 
MIXL1 in U937.  Co-immunoprecipitation assay against Flag-HA-MIXL1 using an 
anti-Flag antibody in 1MIXL, and using an anti-MZF1 antibody to probe the 
immunoblot, with preclear sample as the positive control and IgG-
immunoprecipitated sample as the negative control. MZF1 was detected in the 
preclear lysate and Flag-IP fraction, but not the IgG sample.   
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Figure 17.  MZF1 binds to the same locus as MIXL1 on c-REL promoter.  
Quantitative PCR analysis of the identified c-REL promoter region and c-REL 
intron control region, comparing the abundance of each genomic locus 
immunoprecipitated by either IgG or MZF1 antibodies, normalized to a standard 
curve.  Error bars represent standard deviation between triplicates. * denotes p 
value <0.05 
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Figure 18.  BMP4 induces MIXL1 in CD34+.  MIXL1 expression increased 2-
fold in CD34+ cells treated with BMP4, than untreated or cells treated with TGF-
β.  CD34+ HSPCs from three cord blood donors (47, 51, 60) were treated with 
either 50 ng/ml BMP4 or 2 ng/ml TGF-β1 for 2 hours.  MIXL1 transcript levels 
were quantified by RT-qPCR using 18srRNA as normalization control. Error bars 
represent standard deviation between triplicates and * denotes p value <0.05. 
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8. MIXL1 expressing cells are sensitive to the BMP inhibitor LDN-193189 
As MIXL1 is regulated by the BMP pathway, I postulated that MIXL1-
expressing lines may have increased sensitivity to BMP pathway inhibition.  To 
inhibit BMP pathway activation, I used the ALK2/3/6 (ACVR1, BMPR1A, and 
BMPR1B) inhibitor LDN-193189.  Four high MIXL1-expression cell lines (OCI-
AML2, KG1, ML3 and K562), and two low MIXL1-expression lines (U937 and 
HL60) were exposed to a single treatment of 3 µM LDN-193189 before a 4 day 
incubation, with the relative  survival assayed by the MTS analysis (Figure 19).  
By day 1, the high expression lines were no survival was detected in the LDN-
193189 treated aliquots, while the growth of the low-expression lines was 
diminished compared to the untreated aliquots. However, on the following days, 
HL60 and U937 cell cultures have begun to recover, while the high-expressing 
lines stay undetectable. 
 To further characterize the sensitivity to LDN-193189 in high MIXL1-
expression cell lines, I performed a dose response analysis on each of the 6 lines  
over a 0-700 nM  range of LDN-193189.  Due to the short half-life of LDN-
193189, the medium was changed every 24 hours, and relative survival was 
assayed them by MTS after four days (Figure 20).  The number of cells in the 
low-expression lines U937 and HL60 were constant across all concentrations of 
LDN-193189, suggesting no significant change in growth rate, whereas in the 
high-MIXL1 expression lines, there is a significant decrease between 100 nM and 
200 nM in culture viability. 
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Figure 19. High MIXL1 expression cell lines are sensitive to 3 µM LDN-
193189.  3 µM of LDN-193189 was cytotoxic to OCI-AML2, ML3, KG1 and K562 
in contrast to U937 and HL60cells.  Each cell line was treated with vehicle or 3 
µM LDN-193189 on Day 0, and viability measured every 24 hours by MTS assay, 
in triplicate.  Absorbance was normalized to that of a vehicle-only sample. 
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Figure 20.  High MIXL1 expression cell lines are sensitive to consistent 
exposure of LDN-193189 for 4 days.  OCI-AML2, ML3, KG1 and K562 were 
sensitive to 200 nM LDN-193189, while low MIXL1 expression lines U937 and 
HL60 were unaffected.  Each cell line was treated with 0 nM to 700 nM LDN-
193189, replenished every 24 hours with fresh drug or control medium for 4 
days. Viability on day 4 was assayed then tested by MTS assay in triplicate.  
Absorbance was normalized to that of control vehicle-only treated samples. 
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9. Endogenous MIXL1 in AML Patients 
 To determine if MIXL1 is overexpressed in patient samples, I analyzed the 
TCGA AML patient sample dataset for at least 2-fold change of expression, 
chromosomal modification, or mutation of MIXL1 by the cBioPortal, AML-
associated homeobox transcription factors CDX2 (30), HLX(28), HOXA9 (27), 
and NF-κB pathway members c-REL, BCL2, BCL2A1, and BCL2L1 (Figure 21).  
MIXL1 was amplified or up-regulated in 13% of the total AML cases, while only 
12% of the patients had HOXA9 modifications and 6% had CDX2 modifications.  
HLX was down regulated in 10% of patients and amplified or upregulated in 17%.   
Only a few patient samples contained expression changes in two of these genes, 
implicating MIXL1 expression may be a marker of a subgroup of AML cases 
distinct from HOXA9 and CDX2 expressing AMLs.  
 To determine if MIXL1, HOXA9, and CDX2 characterize distinct 
subgroups, I analyzed the genes for mutual exclusivity between the patient 
samples (Figure 22). While MIXL1 and HOXA9 had a tendency for mutual 
exclusivity, CDX2 had no strong association with either of the two homeoboxes.  
HLX had a tendency to be mutually exclusive with HOXA9, but had a minor 
tendency to co-occur with MIXL1 or CDX2.  
I also performed the same mutual exclusivity analysis with NF-κB pathway 
members c-REL, BCL2, BCL2L1, and BCL2A1.  While both MIXL1 and CDX2 
had a tendency for co-occurrence with c-REL, MIXL1 had a stronger tendency to 
co-occur with BCL2L1, while CDX2 had a stronger tendency to co-occur with 
BCL2.  
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Figure 21. MIXL1 overexpression marks a set of AML cases distinct from 
those expressing CDX2, HLX or HOXA9.  The TCGA AML patient dataset was 
queried through the cBIOPortal database for >2 fold expression alterations as 
determined by RNA-Seq, amplifications, or homozygous deletions, across 166 
AML patient cases.   Each column represents a patient.  MIXL1 is amplified or 
up-regulated in 13% of the total AML cases. 
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Figure 22. MIXL1 expression co-occurs with REL and BCL2L1 expression, 
but not with HOXA9.  A mutual exclusivity analysis from cBioPortal using the 
TCGA AML database as depicted in Figure 21.  Expression of MIXL1 has a 
tendency to co-occur alongside expression of REL and BCL2L1, while 
expression and modification in HOXA9 tend to be excluded from cell lines 
expressing MIXL1 or BCL2L1.  
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I next analyzed TCGA AML patient sample dataset for genes with any of 
the commonly identified somatic mutations (NPM1, FLT3, DNMT3A, TET2 and 
TP53) to determine with which mutations MIXL1 co-occurred or co-operated with 
(Figure 23).  The most common alteration was mutations in TP53 seen in 8 
cases (38%) of MIXL1+ cases. Interestingly, this constitutes 66% of all the cases 
with TP53 mutations (n=12) in the TCGA population.  All of the other recurrent 
mutations were also seen, but less frequently.  Four patients had mutations in 
NPM1; there were three cases each for DNMT3A and TET2. Two patients had 
mutations in FLT3.  
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Figure 23. High MIXL1 expression patient samples contain previously 
identified somatic mutations of AML. 76% (16/21 cases) of high MIXL1 
patients in the TCGA AML patient dataset contained previously identified 
common somatic mutations for AML (NPM1, FLT3, DNMT3A, FLT, JAK3 and 
TP53).  The TCGA AML patient dataset was queried through the cBIOPortal 
database for >2 fold expression alterations, mutations, amplifications, or 
homozygous deletions, across 166 AML patient cases.   Each column represents 
a patient.    
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Chapter 4. Discussion 
In this study I have identified a BMP4-MIXL1-c-REL pathway which may 
have an important role in normal hematopoietic development (Figure 24).   
Mix.1 is induced in Xenopus embryos by BMP4 or Activin A in a SMAD5 
dependent manner (17) although MIXL1 can be induced by TGF-β  in human 
hepatocellular carcinoma (54) and TGF-β and activin mouse ES cells (55) .  
TGF-β from the glial cells within the bone marrow niche is thought to maintain 
HSC quiescence (56)   In humans, BMP2, BMP4 and BMP7 regulate 
maintenance, proliferation and repopulating activities of progenitors (57-59). Our 
studies demonstrate for the first time that MIXL1 induction in human HSPCs by 
BMP4.  At present the distinction between the growth inhibitory versus mitogenic 
response to TGF-β family ligands is dependent on biological assays.  MIXL1 
expression may be a new marker that correlates with a pro-growth/ survival 
response.  
  
1. MIXL1 is over-expressed in a subset of AML  
 Analysis of the TCGA AML patient sample set identified a potentially 
unique subset of high MIXL1 expressing cancers making up 13% of the cancer 
set, a group both distinct and larger than the CDX2 and HOXA9 subtype.  A 
distinct aspect of the MIXL1 expressing cancer set is the prevalence of patients 
with mutated p53: 38% of high-MIXL1 patients had p53 mutations and 67% of 
patients with p53 mutations had high expression of MIXL1.  p53 mutations are 
associated with a strong resistance to chemotherapy (60); if MIXL1 expression is 
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Figure 24.  Proposed BMP/MIXL1/REL pathway.  BMP4 binds to the complex 
between BMP type 2 receptor (BMPR2 or AVCR2A) and BMP type 1 receptor 
kinase (ALK2, ALK3, or ALK6).  In response to activation, the kinase 
phosphorylates SMAD1 or SMAD5 which complexes with SMAD4 to activate the 
transcription of MIXL1.  MIXL1 complexes with MZF1 and activates the 
transcription of c-REL.  C-REL in turn activates the transcription of BCL2 family 
members. 
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prevalent in the p53 mutant subset of AML, then it may identify a new potential 
avenue to treat these untreatable patients. 
While this implicates MIXL1 expression as a potentially strong diagnostic 
marker in leukemia, it will be important to show that this can be replicated in a 
much larger set of patients.  The TCGA dataset contains complete patient data 
for 166 patients of diverse types of AML; however this may not be an accurate 
representation of the distribution of total AML cases.  In addition, the more 
patient information gathered for further analysis, the more reliable and 
statistically significant any correlations determined will be. 
  A number of technical reasons preclude MIXL1 detection in array based 
global expression profiling studies.  In addition to weak probes, the long 3’ UTR 
includes Alu elements which can result in quenched signals.  Thus availability of 
the RNA-Seq data for the TCGA patients provided a valuable resource to 
establish the importance of MIXL1.   
  
2. MIXL1-positive AML lines are sensitive to LDN-193189 
Expression of MIXL1 appears to identify a distinct subset of AML, which is 
of interest if MIXL1 expression also identified a potential therapeutic target.  It 
would be quite relevant, then if the difference in sensitivity to kinase inhibitor 
LDN-193189 seen between MIXL1-expressing lines and non-expressing lines is 
also identified in patient samples. The differential cytotoxicity to 3 µM LDN-
193189, and growth suppression specific to those lines in lower expression 
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levels, implies that this defined subtype of AML may be responsive to Type 1 
BMP receptor kinase suppression.   
 In the experiments presented, I treated a variety of leukemic lines with 
LDN-193189 at concentrations up to 3 μM.  While there was a distinct difference 
between how MIXL1-expressing and non-expressing lines responded below this 
concentration, any concentration at or above 4 μM was lethal to all cell lines 
tested.   One possible explanation for this is that activation of the BMP pathway 
may still be critical to the survival of U937 and HL60, yet this pathway does not 
include MIXL1 activation in these cell lines.  Indeed, the BMP intermediate 
SMAD1 has a different set of targets between U937 and K562 when induced by 
BMP4 (61).  In particular, my survey of their datasets identified that SMAD1 binds 
to a unique peak in the MIXL1 locus in K562 but not U937. 
Another likely explanation above 4 μM for LDN-193189 are lethal to U937 
and HL60 despite the lack of MIXL1 activation is that LDN-193189 may be 
inhibiting other kinases critical to the survival of these lines.  LDN-193189 
functions in BMP signaling suppression by acting as an ATP-antagonist in the 
BMP/Activin-regulated kinases ALK2/3/6 (ACVR1, BMPR1A, and BMPR1B)(62), 
but it can function as an ATP-antagonist in other kinases, including ABL, VEG-
FR, YES1, and CAMKK2 (63), many of which have nearly as high sensitivity to 
the inhibitor as the BMP pathway kinases.  It would therefore be likely that even 
cells not reliant on BMP pathway for survival would have some level of sensitivity 
to the inhibitor. 
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Since LDN-193189 can inhibit a large number of kinases beyond the 
BMP-regulated kinases, it is possible that the sensitivity seen in cell lines with 
high MIXL1 expression is either due to a combination of BMP-regulated kinase 
inhibition and off-target, or off-target effects entirely.  While I have shown that in 
CD34+ hematopoietic precursor cells, MIXL1 can be activated by BMP4, I have 
yet to show that blocking this pathway is critical to the survival of the MIXL1-
expressing cell lines.  Additionally, even within the BMP-regulated kinases 
ALK2/3/6 (ACVR1, BMPR1A, and BMPR1B), I have yet to distinguish what role 
each has and which is most important as a target of LDN-193189 in each cell 
line.   To better identify what role each potential target of LDN-193189 is playing 
in the overall survival of these cell lines, I propose inhibiting each relevant kinase 
through another means, specifically shRNA knockdown, and testing for both 
expression changes in the downstream pathways and changes in growth and 
survival of the cells. 
While LDN-193189 targets a large number of kinases beyond the BMP-
regulated kinases, this may not preclude its use in therapeutics.  Indeed, many of 
the other kinase targets, including ABL1 and VEG-FR, are implicated in cancer 
and are either currently targeted by therapeutics or considered likely targets for 
therapeutics in the future.  LDN-193189 has been already used in rodent models 
of hepcidin induced chronic anemia (64) and fibrodysplasia ossificans 
progressiva with constitutive activation of ACVR1 (65), and the side effects 
exhibited from drug treatment were minimal.  LDN-193189 may have significant 
potential as a generally safe and therapeutic treatment for AML. 
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 3. Transcriptional regulation by MIXL1 in hematopoietic cells 
I identified several important transcriptional targets of MIXL1 in this study.  
While I have focused on c-REL, other critical genes identified by the ChIP-Seq 
study may play a significant role in the leukemogenic activities of MIXL1.  Future 
research will better characterize other downstream targets and elucidate which 
ones are responsible for the function of MIXL1. 
 The expected motif for MIXL1 binding is two TAATTGAATTA. This motif 
was originally identified Gsc (goosecoid) promoter and was confirmed by SELEX 
and reporter assays in ES cells and fibroblasts in vitro SELEX screens (66). The 
expected motif, however, was less abundant in the targeted sequences identified 
by ChIP-Seq than in randomized sequences.  Indeed, while the homeobox 
binding motif is prevalent in AT-rich regions, CG-rich were very abundant in our 
sequences identified by ChIP-Seq.  This is of stark contrast to an analysis of 
Mixl1 targets in mouse embryonic stem cells which had found the homeobox 
binding motif to be considerably enriched (10). 
Several possible reasons underlie the lack of this established DNA binding 
motif in our target peaks.   One possibility is that the MIXL1 is binding directly to 
DNA in a way never previously characterized, which could be tested by purifying 
the MIXL1 protein and testing the binding affinity with different DNA sequences.  
A more likely explanation is that MIXL1 requires interactions with other proteins 
to bind to DNA in this sequence.  This is supported by the abundance of other 
characterized transcription factor binding motifs in the peak regions and the 
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length of the c-REL promoter segment required for MIXL1 regulation, which 
implies a larger multiprotein complex is necessary.  While MIXL1 has been 
shown previously to interact with other homeobox-containing proteins, it has also 
been shown to interact with NEUROD1 (12), which does not contain a homeobox 
domain, in a high throughput two-hybrid screen.  As the most prevalent binding 
motifs identified in the ChIP-Seq were zinc finger motifs, and MZF1 motifs were 
prevalent in the c-REL promoter peak, MZF1 was a potential putative binding 
partner. 
MZF1 (myeloid zinc finger 1) is a zinc finger transcription factor associated 
with the myeloid lineage (67, 68)   Expression of MZF1 inhibits apoptosis and 
differentiation in myeloid leukemia cells (51, 52) and induces proliferation, 
migration, invasion, and metastasis in colorectal cancer, cervical cancer, and 
breast cancer (69-71).  
 Interactions between zinc fingers and homeobox proteins have been 
identified previously.  In breast cancer, an isoform of distal-less homeobox DLX4 
binds to the zinc finger BRCA1 (72).  In hematopoietic cells, zinc finger PML 
binds to the homeobox HHEX (73).  Additionally, a multitude of other potential 
interactions between homeoboxes and zinc fingers have been identified through 
two-hybrid assays (12). 
 Recent studies suggest that Mixl1 can interact with T box factors T, 
Eomes, Tbx6 and Tbx20 directly to form protein complexes which function as 
transcriptional repressors (74) .  Additionally, in a high throughput mammalian 
two hybrid screen, an interaction between TBX20 and MZF1 was identified (12).  
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MIXL1, TBX20, and MZF1 may bind to targets as a multiprotein complex during 
hematopoiesis, similar to the multiprotein complex between paired-type 
homeobox protein NKX2-5, T box protein TBX3, and zinc finger protein GATA4 in 
cardiac development (75). 
 To better identify how MIXL1 is interacting with these gene loci, we would 
need to determine what the subunit composition of the MIXL1-containing 
complexes are.  I would need to repeat co-immunoprecipitation and luciferase 
assay on each combination of potential complex members.   Next, I would want 
to over-express each potential member in every combination to see which 
combinations best activate the transcriptional targets.  Finally, I would knock out 
each member from an expressing AML line to determine the minimal complex 
necessary for transcriptional activation. 
  
4. c-REL is a transcriptional target of MIXL1 
 c-REL is a promising target for MIXL1 transcriptional activation due to its 
strong sequence similarity to the established viral oncogene v-REL and 
established role in the activation of anti-apoptotic genes BCL2L1 and BCL2A1 
(76). Amplification and overexpression of c-REL is implicated in diffuse large B 
cell lymphoma (38). c-REL overexpression is seen in a wide array of other 
cancer types, including colorectal cancer (77), breast cancer (78), lung 
carcinoma (79), squamous cell carcinoma (80, 81), retinoblastoma (82),  
endometrial carcinoma (83), and pancreatic cancers (84).   
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Activity of the NF-κB DNA binding factors comprising of 5 proteins which 
heterodimerize to bind DNA, is regulated both at the transcriptional and post- 
transcriptional level.  Cytoplasmic sequestration of the five proteins by inhibitors 
NFKBIA, B and E regulates their activity post-transcriptionally (85). Expression 
profiling suggests down regulation of all the NFKBI members and preferential 
upregulation of c-REL, RELB and NFKB2.  Furthermore, recent evidence 
suggests potential functional differences in the activity depending upon the 
subunit composition. Thus c-REL homodimers or heterodimer with NFKB2 or 
RELB may have varied responses (37, 86).  Notably, there is an absolute 
requirement for c-REL in B lymphoid development (87), though the factors 
surrounding both the regulation of c-REL and the downstream effects distinct 
from the other family members is currently unknown.  Overall, this would 
implicate that MIXL1 and c-REL may activate preferentially a “non-canonical” NF-
κB pathway distinct from the one regulated by the RELA/NFKB1 complex. 
     
5. Summary 
 In summation, we have identified MIXL1 to mark a new subset of AML and 
c-REL as a direct transcriptional target of MIXL1. Targeting the BMP receptor 
upstream of MIXL1 may be a novel therapeutic avenue to explore in AML. 
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Appendix: Peaks identified by all analyses of the MIXL-overexpression 
ChIP-Seq dataset.  The following set of peaks was generated by normalizing to 
the two control samples in three combinations and then finding the overlapping 
set (as visualized in Figure 5): Flag-1MIXL to IgG-Control and Flag-Control, Flag-
2MIXL to IgG-Control and Flag-Control, and Flag-1MIXL and Flag-2MIXL 
combined to IgG-Control and Flag-Control. A total of 179 peaks were identified in 
this stringent set. This table was generated as part of the analysis performed by 
Dr. Yue Lu and Dr. Shoudan Liang for ChIP-seq.  Columns are as followed:  
Site position:  The location of the peak on Human genome assembly 
Hg18/NCBI36.   
Gene name: Gene loci within 25 kb of the peak. 
Location: Relative location of the peak to the nearest gene loci.  Designations 
are:  Upstream – 5 to 25 kb upstream of the transcription start site (TSS), 
Promoter – 0 kb to 5 kb upstream of the TSS, Body – Between the TSS and 
transcription sequence end (TSE), TSE – 0 to 5 kb downstream of the 
transcription sequence end, Downstream – 5 to 25 kb downstream of the TSE.  
Unlabelled have no nearby loci. 
Fold enrichment: Fold enrichment of the peak region in experimental sets over 
control sets. 
Number of Tags: The number of sequence tags that contributed to this peak. 
-10Log (pvalue): Negative Log base ten of the p-value for each peak. 
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